Jasper Therapeutics, Inc.
Jasper Therapeutics, Inc. (Nasdaq: JSPR) is a clinical-stage biotechnology company developing therapies for mast cell-driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria and asthma. Its lead product candidate, briquilimab, is a monoclonal antibody designed to block signaling through… From the company’s description.
In fiscal 2025, Jasper Therapeutics, Inc. reported a net loss of $75.80M. Operations used $77.16M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Jasper Therapeutics, Inc. does
In the company’s own words
Jasper Therapeutics, Inc. (Nasdaq: JSPR) is a clinical-stage biotechnology company developing therapies for mast cell-driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria and asthma. Its lead product candidate, briquilimab, is a monoclonal antibody designed to block signaling through the KIT receptor and deplete mast cells. Clinical programs evaluate briquilimab in chronic urticarias and allergic asthma, while the company also considers other mast cell-related indications. Jasper previously developed briquilimab for stem cell transplant conditioning, including in severe combined immunodeficiency, but discontinued those programs in 2025 to focus on mast cell diseases. The company holds worldwide exclusive development and commercialization rights to briquilimab through a license from Amgen, alongside a Stanford license for its use in stem cell transplantation. Jasper reports as a single business focused on research and development; it had no product sales and reported no revenue for fiscal 2025. Its website is https://www.jaspertherapeutics.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- REDWOOD CITY, CA
- Fiscal year end
- December
- CIK
- 1788028
- SIC
- 2836
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Jasper Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Jasper Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Jasper Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Jasper Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Jasper Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”